All Oncology News

Sarah M. Larson, MD, discusses trials with the potential to shift treatment strategies in the frontline and relapsed/refractory settings of multiple myeloma and remaining research questions in the field.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion to recommend approval of the combination of avelumab and axitinib for the frontline treatment of adult patients with advanced renal cell carcinoma.

Serial assessment of blood-based immune markers showed that the risk of progression from monoclonal gammopathy of undetermined significance, the precursor disease to multiple myeloma is fluctuating rather than determinate, and these patients can experience progression to myeloma within 5 years.

Gary J. Schiller, MD, discusses therapeutic advances, the importance of genomic testing, and other agents in the pipeline for acute myeloid leukemia.

Gastrointestinal oncology experts highlight what they are most excited for at the upcoming International Society of Gastrointestinal Oncology 16th Annual Gastrointestinal Oncology Conference.

Arek Z. Dudek, MD, PhD, discusses the research surrounding osimertinib in the treatment of patients with EGFR-positive non–small cell lung cancer.

Herbert A. Eradat, MD, explains how insight into the pathogenesis of chronic lymphocytic leukemia is leading to novel treatment strategies and shed light on unmet needs in the field.

Sylvia Adams, MD, discusses the biology of triple-negative breast cancer, data sparking excitement in the field, and intriguing trials on the horizon.

Christopher S. Seet, MD, PhD, discusses elements of treatment discontinuation in chronic myeloid leukemia.

Leonard G. Gomella, MD, FACS, discusses the role of genetic testing and emerging biomarkers in prostate cancer.

David Bond, MD, addresses the ongoing challenge of second primary neoplasia in chronic lymphocytic leukemia.

Michael Wang, MD, discusses how the mantle cell lymphoma paradigm is facing a time of exploration, as researchers examine different therapeutic options beyond chemotherapy.

Patients with metastatic colorectal cancer who harbored BRAF non-V600, RAS-dependent mutations were more likely to respond to anti-EGFR therapy versus those with BRAF non-V600, RAS-independent mutations.

The FDA has approved apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer.

The combination of cabazitaxel in combination with carboplatin demonstrated an improvement in progression-free survival versus cabazitaxel alone in men with metastatic castration-resistant prostate cancer.

Although several newer JAK inhibitors are being investigated, such as pacritinib, momelotinib, and the recently FDA-approved fedratinib, most combinations are being explored in combination with ruxolitinib.

The International Society of Gastrointestinal Oncology, a not-for-profit global educational organization committed to gastrointestinal oncology, will host the 16th Annual Gastrointestinal Oncology Conference from Oct. 10-11, 2019 at the Hilton Crystal City in Arlington, Virginia.

The FDA has granted an accelerated approval to the combination of lenvatinib and pembrolizumab for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient, and who have disease progression following prior systemic therapy but are ineligible for curative surgery or radiation.

Alex A. Adjei, MD, PhD, a professor of oncology and pharmacology at Mayo Clinic, discussed the history of five target genes: NTRK, RET, MET, BRAF, and HER2, as well as the exciting data coming out for the lung cancer subset.

Toni Choueiri, MD, discusses the rationale behind the Kidney Cancer Research Summit and recent advances in the renal cell carcinoma landscape.

Shubhada Dhage, MD, FACS, discusses the role of surgery and other therapeutic modalities in breast cancer and explained the shift toward de-escalated treatments and less morbid surgical management strategies.

Naomi Fujioka, MD, discusses the clinical implications of the PACIFIC trial in NSCLC treatment and additional questions that are informing planned and ongoing trial designs in stage III disease.

Adding daratumumab to carfilzomib and dexamethasone improved progression-free survival in patients with relapsed/refractory multiple myeloma, according to topline findings from the phase III CANDOR study.

Gary H. Lyman, MD, MPH, discusses the current parameters used to develop a biosimilar, the impact these products have had in the treatment and supportive care settings, and ongoing initiatives to address remaining challenges.

Joseph Leach, MD, a medical oncologist at Minnesota Oncology, discussed the emergence of ALK inhibitors in lung cancer and the importance of testing for such molecular abnormalities.

Joshua P. Sasine, MD, PhD, spotlights some of the strategies under investigation to improve the safety and efficacy of CAR T-cell therapy in hematologic malignancies.

The FDA has granted a priority review designation to a biologics license application for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting.

Ochsner Cancer Institute (Ochsner), along with its Gulf South NCI Community Oncology Research Program (NCORP) partners, has been awarded a $13.6 million grant by the National Cancer Institute to expand the successful statewide clinical trials network with a special emphasis on minority and underserved cancer patients.

The FDA is updating the prescribing information and Patient Package Insert for CDK4/6 inhibitors to include a warning that the treatments in rare cases may cause severe inflammation of the lungs.

A fixed-dose subcutaneous injection of pertuzumab and trastuzumab with hyaluronidase in combination with intravenous chemotherapy demonstrated noninferior pharmacokinetics compared with the standard IV infusions of the regimen in patients with HER2-positive early breast cancer, meeting the primary endpoint of the phase III FeDeriCa trial (NCT03493854).